HIV-1 infection of female genital tract tissue for use in prevention studies

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 5, 2013, Pages 548-554

  Dezzutti, Charlene S ^a,b   Uranker, Kevin ^b   Bunge, Katherine E ^a   Richardson Harman, Nicola ^c   Macio, Ingrid ^d   Hillier, Sharon L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c ALPHA STATCONSULT LLC   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Bioindicator; Explants; HIV prevention; Microbicides; Mucosal tissue susceptibility; Pre exposure prophylaxis

Indexed keywords

CHLORHEXIDINE; LIDOCAINE;

ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; FEMALE GENITAL SYSTEM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PREVENTION STUDY; PRIORITY JOURNAL; PROBABILITY; UTERINE CERVIX BIOPSY; VAGINA;

ADULT; ANTI-INFECTIVE AGENTS; BIOPSY; DISEASE TRANSMISSION, INFECTIOUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENITALIA, FEMALE; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; YOUNG ADULT;

EID: 84883459789     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318291f331     Document Type: Article

References (24)

1. Abner SR, Guenthner PC, Guarner J, et al. A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J Infect Dis. 2005;192:1545-1556.
2. Cummins JE Jr, Guarner J, Flowers L, et al. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob Agents Chemother. 2007;51:1770-1779.
3. Fletcher PS, Elliott J, Grivel JC, et al. Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS. 2006;20: 1237-1245.
4. Greenhead P, Hayes P, Watts PS, et al. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol. 2000;74:5577-5586.
5. Anton PA, Cranston RD, Kashuba A, et al. RMP-02/MTN-006: a phase 1 rectal safety, acceptability, pharmacokinetic and pharmacodynamic study of tenofovir 1% gel compared to oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses. 2012;28:1412-1421.
6. Anton PA, Saunders T, Elliott J, et al. First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One. 2011;6:e23243.
7. Richardson-Harman N, Mauck C, McGowan I, et al. Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study. AIDS Res Hum Retroviruses. 2012;28:1422-1433.
8. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg. 1938;27:493-497.
9. Richardson-Harman N, Lackman-Smith C, Fletcher PS, et al. Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. J Clin Microbiol. 2009;47:3530-3539.
10. Baqui AA, Kelley JI, Jabra-Rizk MA, et al. In vitro effect of oral antiseptics on human immunodeficiency virus-1 and herpes simplex virus type 1. J Clin Periodontol. 2001;28:610-616.
11. Yu HP. Role of anesthetic agents on cardiac and immune systems. Shock. 2011;36:532-541.
12. Pudney J, Quayle AJ, Anderson DJ. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod. 2005; 73:1253-1263.
13. Ildgruben AK, Sjoberg IM, Hammarstrom ML. Influence of hormonal contraceptives on the immune cells and thickness of human vaginal epithelium. Obstet Gynecol. 2003;102:571-582.
14. McKinnon LR, Nyanga B, Chege D, et al. Characterization of a human cervical CD4+ T cell subset coexpressing multiple markers of HIV susceptibility. J Immunol. 2011;187:6032-6042.
15. Anton PA, Elliott J, Poles MA, et al. Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS. 2000;14:1761-1765.
16. Fuchs EJ, Grohskopf LA, Lee LA, et al. Detecting Rectal Epithelial Disruption Using Radioisotopes: A Simple Test to Identify Potential HIV Microbicide Toxicity. Microbicide 2008. New Delhi, India; 2008. Abstract #209.
17. Chandra N, Thurman AR, Anderson S, et al. Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues. AIDS Res Hum Retroviruses. 2013;29:592-601.
18. Marx PA, Spira AI, Gettie A, et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med. 1996;2:1084-1089.
19. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2012;12:19-26.
20. Cone RA, Hoen T, Wong X, et al. Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis. 2006;6:90.
21. Achilles SL, Shete PB, Whaley KJ, et al. Microbicide efficacy and toxicity tests in a mouse model for vaginal transmission of Chlamydia trachomatis. Sex Transm Dis. 2002;29:655-664.
22. Gupta P, Ratner D, Patterson BK, et al. Use of frozen-thawed cervical tissues in the organ culture system to measure anti-HIV activities of candidate microbicides. AIDS Res Hum Retroviruses. 2006;22:419-424.
23. McGowan I, Tanner K, Elliott J, et al. Nonreproducibility of "snap-frozen" rectal biopsies for later use in ex vivo explant infectibility studies. AIDS Res Hum Retroviruses. 2012;28:1509-1512.
24. Mazur P. Freezing of living cells: mechanisms and implications. Am J Physiol. 1984;247:C125-C142.